On January 9, Covidien announced it had acquired CV Ingenuity. We are extremely pleased to join forces with Covidien, the market leader in the treatment of vascular disease. We believe this transaction reflects the increasing market opportunity represented by our drug coated balloon technology, which is substantiated by a strong intellectual property portfolio and research capability. The combination of Covidien's market leadership in the vascular space with CV Ingenuity's drug coated balloon technology will allow us to, as one team, continue to improve the care of patients suffering from vascular disease.
We at CV Ingenuity are extremely excited by the synergies of this combination and we wanted to take this opportunity to update you. To learn more about the transaction, please click here.
Duke Rohlen
President & CEO
CV Ingenuity